April 16 (Reuters) - AstraZeneca PLC:
* UPDATED OVERALL SURVIVAL DATA FOR LYNPARZA® (OLAPARIB) IN GBRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER PRESENTED AT AACR
* ASTRAZENECA- TRIAL COMPARED LYNPARZA WITH CHEMOTHERAPY FOR PATIENTS WITH GERMLINE BRCA-MUTATED HER2-NEGATIVE METASTATIC BREAST CANCER, MET PRIMARY ENDPOINT Source text for Eikon: Further company coverage: